Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Depreciation & Amortization (CF) (2018 - 2025)

BioNexus Gene Lab's Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $29001.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 15.37% year-over-year to $29001.0; the TTM value through Sep 2025 reached $28970.0, down 69.41%, while the annual FY2024 figure was $104160.0, 25.11% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $29001.0 at BioNexus Gene Lab, up from $27800.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $63129.0 in Q3 2023 and bottomed at -$54473.0 in Q4 2024.
  • The 5-year median for Depreciation & Amortization (CF) is $22466.0 (2021), against an average of $19449.6.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 254.67% in 2021 before it tumbled 370.93% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $22794.0 in 2021, then grew by 8.88% to $24819.0 in 2022, then decreased by 18.99% to $20106.0 in 2023, then crashed by 370.93% to -$54473.0 in 2024, then surged by 153.24% to $29001.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Depreciation & Amortization (CF) are $29001.0 (Q3 2025), $27800.0 (Q2 2025), and $26642.0 (Q1 2025).